Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Prostate Cancer

  Free Subscription

Articles published in BMC Cancer

Retrieve available abstracts of 220 articles:
HTML format

Single Articles

    July 2021
  1. IMADA EL, Sanchez DF, Dinalankara W, Vidotto T, et al
    Transcriptional landscape of PTEN loss in primary prostate cancer.
    BMC Cancer. 2021;21:856.
    PubMed     Abstract available

  2. MANGIOLA S, McCoy P, Modrak M, Souza-Fonseca-Guimaraes F, et al
    Transcriptome sequencing and multi-plex imaging of prostate cancer microenvironment reveals a dominant role for monocytic cells in progression.
    BMC Cancer. 2021;21:846.
    PubMed     Abstract available

    June 2021
  3. CHONG W, Zhang Z, Luo R, Gu J, et al
    Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients.
    BMC Cancer. 2021;21:655.
    PubMed     Abstract available

    May 2021
  4. ELLIS SD, Hwang S, Morrow E, Kimminau KS, et al
    Perceived barriers to the adoption of active surveillance in low-risk prostate cancer: a qualitative analysis of community and academic urologists.
    BMC Cancer. 2021;21:649.
    PubMed     Abstract available

  5. OKAMOTO T, Noro D, Hatakeyama S, Narita S, et al
    Impact of pretreatment anemia on upfront abiraterone acetate therapy for metastatic hormone-sensitive prostate cancer: a multicenter retrospective study.
    BMC Cancer. 2021;21:605.
    PubMed     Abstract available

  6. SHAH S, Beckmann K, Van Hemelrijck M, Challacombe B, et al
    Guy's and St Thomas NHS Foundation active surveillance prostate cancer cohort: a characterisation of a prostate cancer active surveillance database.
    BMC Cancer. 2021;21:573.
    PubMed     Abstract available

  7. MA TM, Lamb JM, Casado M, Wang X, et al
    Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial.
    BMC Cancer. 2021;21:538.
    PubMed     Abstract available

  8. CALAIS J, Zhu S, Hirmas N, Eiber M, et al
    Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol.
    BMC Cancer. 2021;21:512.
    PubMed     Abstract available

  9. AHETO JMK, Utuama OA, Dagne GA
    Geospatial analysis, web-based mapping and determinants of prostate cancer incidence in Georgia counties: evidence from the 2012-2016 SEER data.
    BMC Cancer. 2021;21:508.
    PubMed     Abstract available

  10. TAKESHIMA Y, Yamada Y, Teshima T, Fujimura T, et al
    Clinical significance and risk factors of International Society of Urological Pathology (ISUP) grade upgrading in prostate cancer patients undergoing robot-assisted radical prostatectomy.
    BMC Cancer. 2021;21:501.
    PubMed     Abstract available

    April 2021
  11. LEE J, Yang SW, Jin L, Lee CL, et al
    Is PSA density of the peripheral zone as a useful predictor for prostate cancer in patients with gray zone PSA levels?
    BMC Cancer. 2021;21:472.
    PubMed     Abstract available

  12. WATANABE D, Kimura T, Watanabe K, Takano H, et al
    Effects of once-yearly zoledronic acid on bone density and incident vertebral fractures in nonmetastatic castration-sensitive prostate cancer patients with osteoporosis.
    BMC Cancer. 2021;21:422.
    PubMed     Abstract available

  13. LIN H, Liu Q, Zeng X, Yu W, et al
    Pembrolizumab with or without enzalutamide in selected populations of men with previously untreated metastatic castration-resistant prostate cancer harbouring programmed cell death ligand-1 staining: a retrospective study.
    BMC Cancer. 2021;21:399.
    PubMed     Abstract available

  14. NGUYEN HTN, Xue H, Firlej V, Ponty Y, et al
    Reference-free transcriptome signatures for prostate cancer prognosis.
    BMC Cancer. 2021;21:394.
    PubMed     Abstract available

    March 2021
  15. WIND A, Hartman ED, Van Eekeren RRJP, Wijn RPWF, et al
    Validating a generic cancer consumer quality index in eight European countries, patient reported experiences and the influence of cultural differences.
    BMC Cancer. 2021;21:231.
    PubMed     Abstract available

  16. WONG SK, Hamm J, Shokoohi A, McGahan CE, et al
    Real world duration of curative intent breast, colorectal, non-small cell lung, and prostate cancer treatment.
    BMC Cancer. 2021;21:215.
    PubMed     Abstract available

    February 2021
  17. KIM B, Jung S, Kim H, Kwon JO, et al
    The role of S100A4 for bone metastasis in prostate cancer cells.
    BMC Cancer. 2021;21:137.
    PubMed     Abstract available

  18. MARCELLUS KA, Crawford Parks TE, Almasi S, Jasmin BJ, et al
    Distinct roles for the RNA-binding protein Staufen1 in prostate cancer.
    BMC Cancer. 2021;21:120.
    PubMed     Abstract available

  19. THUREAU S, Marchesi V, Vieillard MH, Perrier L, et al
    Efficacy of extracranial stereotactic body radiation therapy (SBRT) added to standard treatment in patients with solid tumors (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases: study protocol for a randomised phase II
    BMC Cancer. 2021;21:117.
    PubMed     Abstract available

    January 2021
  20. MEUNIER ME, Blanchet P, Neuzillet Y, Lebret T, et al
    A review of new hormonal therapies for prostate cancer in black men: is there enough data?
    BMC Cancer. 2021;21:61.
    PubMed     Abstract available

  21. ZHANG PF, Xie D, Li Q
    Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance.
    BMC Cancer. 2021;21:35.
    PubMed     Abstract available

  22. WU L, Quan W, Yue G, Luo Q, et al
    Identification of a novel six autophagy-related genes signature for the prognostic and a miRNA-related autophagy predictor for anti-PD-1 therapy responses in prostate cancer.
    BMC Cancer. 2021;21:15.
    PubMed     Abstract available

    December 2020
  23. FREYTAG M, Kluth M, Bady E, Hube-Magg C, et al
    Epithelial splicing regulatory protein 1 and 2 (ESRP1 and ESRP2) upregulation predicts poor prognosis in prostate cancer.
    BMC Cancer. 2020;20:1220.
    PubMed     Abstract available

  24. LUND ME, Howard CB, Thurecht KJ, Campbell DH, et al
    A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells.
    BMC Cancer. 2020;20:1214.
    PubMed     Abstract available

  25. DODLA P, Bhoopalan V, Khoo SK, Miranti C, et al
    Gene expression analysis of human prostate cell lines with and without tumor metastasis suppressor CD82.
    BMC Cancer. 2020;20:1211.
    PubMed     Abstract available

    November 2020
  26. HERNANDEZ VARGAS JA, Ramirez Barbosa PX, Gil Quijano AM, Valbuena AM, et al
    Patterns of breast, prostate and cervical cancer incidence and mortality in Colombia: an administrative registry data analysis.
    BMC Cancer. 2020;20:1097.
    PubMed     Abstract available

    October 2020
  27. MENG Y, Hu X, Li S, Zeng X, et al
    miR-203 inhibits cell proliferation and ERK pathway in prostate cancer by targeting IRS-1.
    BMC Cancer. 2020;20:1028.
    PubMed     Abstract available

  28. MENDEZ LC, Arifin AJ, Bauman GS, Velker VM, et al
    Is hypofractionated whole pelvis radiotherapy (WPRT) as well tolerated as conventionally fractionated WPRT in prostate cancer patients? The HOPE trial.
    BMC Cancer. 2020;20:978.
    PubMed     Abstract available

  29. SANGHERA S, Mohiuddin S, Coast J, Garfield K, et al
    Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial.
    BMC Cancer. 2020;20:971.
    PubMed     Abstract available

  30. KAMDAR S, Fleshner NE, Bapat B
    A 38-gene model comprised of key TET2-associated genes shows additive utility to high-risk prostate cancer cases in the prognostication of biochemical recurrence.
    BMC Cancer. 2020;20:953.
    PubMed     Abstract available

    September 2020
  31. KAWAHARA T, Kato M, Tabata K, Kojima I, et al
    A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment.
    BMC Cancer. 2020;20:919.
    PubMed     Abstract available

  32. WANG Y, Dong X, Qu Z, Peng K, et al
    Correlation between peripheral blood neutrophil-lymphocyte ratio and CD34 expression in prostate cancer.
    BMC Cancer. 2020;20:900.
    PubMed     Abstract available

  33. ANG M, Borg M, O'Callaghan ME
    Survival outcomes in men with a positive family history of prostate cancer: a registry based study.
    BMC Cancer. 2020;20:894.
    PubMed     Abstract available

  34. PRIVE BM, Janssen MJR, van Oort IM, Muselaers CHJ, et al
    Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial.
    BMC Cancer. 2020;20:884.
    PubMed     Abstract available

    August 2020
  35. CARIO CL, Chen E, Leong L, Emami NC, et al
    A machine learning approach to optimizing cell-free DNA sequencing panels: with an application to prostate cancer.
    BMC Cancer. 2020;20:820.
    PubMed     Abstract available

  36. IGARASHI K, Yui Y, Watanabe K, Kumai J, et al
    Molecular evidence of IGFBP-3 dependent and independent VD3 action and its nonlinear response on IGFBP-3 induction in prostate cancer cells.
    BMC Cancer. 2020;20:802.
    PubMed     Abstract available

  37. HOUEDE N, Rebillard X, Bouvet S, Kabani S, et al
    Impact on quality of life 3 years after diagnosis of prostate cancer patients below 75 at diagnosis: an observational case-control study.
    BMC Cancer. 2020;20:757.
    PubMed     Abstract available

  38. CHEN J, Liu X, Ke K, Zou J, et al
    LINC00992 contributes to the oncogenic phenotypes in prostate cancer via targeting miR-3935 and augmenting GOLM1 expression.
    BMC Cancer. 2020;20:749.
    PubMed     Abstract available

  39. JAMIESON L, Forster MD, Zaki K, Mithra S, et al
    Immunotherapy and associated immune-related adverse events at a large UK centre: a mixed methods study.
    BMC Cancer. 2020;20:743.
    PubMed     Abstract available

  40. DONSWIJK ML, van Leeuwen PJ, Vegt E, Cheung Z, et al
    Clinical impact of PSMA PET/CT in primary prostate cancer compared to conventional nodal and distant staging: a retrospective single center study.
    BMC Cancer. 2020;20:723.
    PubMed     Abstract available

    July 2020
  41. MATSUYAMA H, Matsubara N, Kazama H, Seto T, et al
    Real-world efficacy and safety of two doses of cabazitaxel (20 or 25 mg/m(2)) in patients with castration-resistant prostate cancer: results of a Japanese post-marketing surveillance study.
    BMC Cancer. 2020;20:649.
    PubMed     Abstract available

  42. WOLLERSHEIM BM, van Asselt KM, van der Poel HG, van Weert HCPM, et al
    Design of the PROstate cancer follow-up care in Secondary and Primary hEalth Care study (PROSPEC): a randomized controlled trial to evaluate the effectiveness of primary care-based follow-up of localized prostate cancer survivors.
    BMC Cancer. 2020;20:635.
    PubMed     Abstract available

  43. WRIGHT CM, Halkett G, Carey Smith R, Moorin R, et al
    Sarcoma epidemiology and cancer-related hospitalisation in Western Australia from 1982 to 2016: a descriptive study using linked administrative data.
    BMC Cancer. 2020;20:625.
    PubMed     Abstract available

    June 2020
  44. CASARIN S, Dondossola E
    An agent-based model of prostate Cancer bone metastasis progression and response to Radium223.
    BMC Cancer. 2020;20:605.
    PubMed     Abstract available

  45. CHOI JB, Myong JP, Lee Y, Kim I, et al
    Does increased body mass index lead to elevated prostate cancer risk? It depends on waist circumference.
    BMC Cancer. 2020;20:589.
    PubMed     Abstract available

  46. MEHDI A, Cheishvili D, Arakelian A, Bismar TA, et al
    DNA methylation signatures of Prostate Cancer in peripheral T-cells.
    BMC Cancer. 2020;20:588.
    PubMed     Abstract available

  47. KNAUL FM, Doubova SV, Gonzalez Robledo MC, Durstine A, et al
    Self-identity, lived experiences, and challenges of breast, cervical, and prostate cancer survivorship in Mexico: a qualitative study.
    BMC Cancer. 2020;20:577.
    PubMed     Abstract available

  48. BOU-DARGHAM MJ, Sha L, Sang QA, Zhang J, et al
    Immune landscape of human prostate cancer: immune evasion mechanisms and biomarkers for personalized immunotherapy.
    BMC Cancer. 2020;20:572.
    PubMed     Abstract available

  49. LIN E, Garmo H, Van Hemelrijck M, Adolfsson J, et al
    Association of type 2 diabetes mellitus and antidiabetic medication with risk of prostate cancer: a population-based case-control study.
    BMC Cancer. 2020;20:551.
    PubMed     Abstract available

  50. LI Q, Shi Y, Sa R, Hao J, et al
    Altered staining patterns and expression level of Engrailed-2 in benign prostatic hyperplasia and prostate Cancer predict prostatic disease progression.
    BMC Cancer. 2020;20:555.
    PubMed     Abstract available

  51. HASAN H, Deek MP, Phillips R, Hobbs RF, et al
    A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS).
    BMC Cancer. 2020;20:492.
    PubMed     Abstract available

    May 2020
  52. NILSSEN Y, Brustugun OT, Eriksen MT, Haug ES, et al
    Patient and tumour characteristics associated with inclusion in Cancer patient pathways in Norway in 2015-2016.
    BMC Cancer. 2020;20:488.
    PubMed     Abstract available

  53. MEYER HJ, Wienke A, Surov A
    Discrimination between clinical significant and insignificant prostate cancer with apparent diffusion coefficient - a systematic review and meta analysis.
    BMC Cancer. 2020;20:482.
    PubMed     Abstract available

  54. TRAN MGB, Bibby BAS, Yang L, Lo F, et al
    Independence of HIF1a and androgen signaling pathways in prostate cancer.
    BMC Cancer. 2020;20:469.
    PubMed     Abstract available

  55. BERGHEN C, Joniau S, Rans K, Devos G, et al
    Metastasis-directed therapy in castration-refractory prostate cancer (MEDCARE): a non-randomized phase 2 trial.
    BMC Cancer. 2020;20:457.
    PubMed     Abstract available

  56. VUOLUKKA K, Auvinen P, Palmgren JE, Aaltomaa S, et al
    Incidence of subsequent primary cancers and radiation-induced subsequent primary cancers after low dose-rate brachytherapy monotherapy for prostate cancer in long-term follow-up.
    BMC Cancer. 2020;20:453.
    PubMed     Abstract available

  57. DUDKA I, Thysell E, Lundquist K, Antti H, et al
    Comprehensive metabolomics analysis of prostate cancer tissue in relation to tumor aggressiveness and TMPRSS2-ERG fusion status.
    BMC Cancer. 2020;20:437.
    PubMed     Abstract available

  58. MOORE C, Palau VE, Mahboob R, Lightner J, et al
    Upregulation of pERK and c-JUN by gamma-tocotrienol and not alpha-tocopherol are essential to the differential effect on apoptosis in prostate cancer cells.
    BMC Cancer. 2020;20:428.
    PubMed     Abstract available

  59. QIU C, Bai Y, Yin T, Miao X, et al
    Targeted imaging of orthotopic prostate cancer by using clinical transformable photoacoustic molecular probe.
    BMC Cancer. 2020;20:419.
    PubMed     Abstract available

  60. DE BRUYCKER A, Spiessens A, Dirix P, Koutsouvelis N, et al
    PEACE V - Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial.
    BMC Cancer. 2020;20:406.
    PubMed     Abstract available

  61. MILLER ET, You S, Cadaneanu RM, Kim M, et al
    Chromosomal instability in untreated primary prostate cancer as an indicator of metastatic potential.
    BMC Cancer. 2020;20:398.
    PubMed     Abstract available

  62. WANG S, Zhou X, Liang C, Bao M, et al
    ALDH1A3 serves as a predictor for castration resistance in prostate cancer patients.
    BMC Cancer. 2020;20:387.
    PubMed     Abstract available

  63. WANG M, Wasserman E, Geyer N, Carroll RM, et al
    Spatial patterns in prostate Cancer-specific mortality in Pennsylvania using Pennsylvania Cancer registry data, 2004-2014.
    BMC Cancer. 2020;20:394.
    PubMed     Abstract available

  64. TAGUCHI S, Uemura Y, Fujimura T, Morikawa T, et al
    Quantification of the individual risk of each Gleason pattern, including tertiary Gleason pattern 5, after radical prostatectomy: development of the modified Gleason grade grouping (mGGG) model.
    BMC Cancer. 2020;20:371.
    PubMed     Abstract available

    April 2020
  65. LI B, Lu Z, Wang S, Hou J, et al
    Pretreatment elevated prognostic nutritional index predicts a favorable prognosis in patients with prostate cancer.
    BMC Cancer. 2020;20:361.
    PubMed     Abstract available

  66. OEHUS AK, Kroeze SGC, Schmidt-Hegemann NS, Vogel MME, et al
    Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy.
    BMC Cancer. 2020;20:362.
    PubMed     Abstract available

  67. ZHENG Z, Zhou Z, Yan W, Zhou Y, et al
    Tumor characteristics, treatments, and survival outcomes in prostate cancer patients with a PSA level < 4 ng/ml: a population-based study.
    BMC Cancer. 2020;20:340.
    PubMed     Abstract available

  68. CHEN JJ, Zhu ZS, Zhu YY, Shi HQ, et al
    Applied anatomy of pelvic lymph nodes and its clinical significance for prostate cancer:a single-center cadaveric study.
    BMC Cancer. 2020;20:330.
    PubMed     Abstract available

  69. LEHTONEN M, Heiskanen L, Reinikainen P, Kellokumpu-Lehtinen PL, et al
    Both comorbidity and worse performance status are associated with poorer overall survival after external beam radiotherapy for prostate cancer.
    BMC Cancer. 2020;20:324.
    PubMed     Abstract available

  70. MATSUDA Y, Narita S, Nara T, Mingguo H, et al
    Impact of nuclear YAP1 expression in residual cancer after neoadjuvant chemohormonal therapy with docetaxel for high-risk localized prostate cancer.
    BMC Cancer. 2020;20:302.
    PubMed     Abstract available

  71. CHEN C, Cai Z, Zhuo Y, Xi M, et al
    Overexpression of SLC6A1 associates with drug resistance and poor prognosis in prostate cancer.
    BMC Cancer. 2020;20:289.
    PubMed     Abstract available

    March 2020
  72. SONG H, Jin S, Xiang P, Hu S, et al
    Prognostic value of the bone scan index in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.
    BMC Cancer. 2020;20:238.
    PubMed     Abstract available

  73. SIMMONS AD, Nguyen M, Pintus E
    Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report.
    BMC Cancer. 2020;20:215.
    PubMed     Abstract available

    February 2020
  74. ZHOU X, Ning Q, Jin K, Zhang T, et al
    Development and validation of a preoperative nomogram for predicting survival of patients with locally advanced prostate cancer after radical prostatectomy.
    BMC Cancer. 2020;20:97.
    PubMed     Abstract available

  75. BUWENGE M, Scirocco E, Deodato F, Macchia G, et al
    Radiotherapy of prostate cancer: impact of treatment characteristics on the incidence of second tumors.
    BMC Cancer. 2020;20:90.
    PubMed     Abstract available

    January 2020
  76. KAWAMURA H, Kubo N, Sato H, Mizukami T, et al
    Moderately hypofractionated carbon ion radiotherapy for prostate cancer; a prospective observational study "GUNMA0702".
    BMC Cancer. 2020;20:75.
    PubMed     Abstract available

  77. NAWAS AF, Kanchwala M, Thomas-Jardin SE, Dahl H, et al
    IL-1-conferred gene expression pattern in ERalpha(+) BCa and AR(+) PCa cells is intrinsic to ERalpha(-) BCa and AR(-) PCa cells and promotes cell survival.
    BMC Cancer. 2020;20:46.
    PubMed     Abstract available

    December 2019
  78. LIAO KM, Huang YB, Chen CY, Kuo CC, et al
    Risk of ischemic stroke in patients with prostate cancer receiving androgen deprivation therapy in Taiwan.
    BMC Cancer. 2019;19:1263.
    PubMed     Abstract available

  79. ZHEN L, Liu X, Yegang C, Yongjiao Y, et al
    Accuracy of multiparametric magnetic resonance imaging for diagnosing prostate Cancer: a systematic review and meta-analysis.
    BMC Cancer. 2019;19:1244.
    PubMed     Abstract available

  80. ZONI E, Minoli M, Bovet C, Wehrhan A, et al
    Preoperative plasma fatty acid metabolites inform risk of prostate cancer progression and may be used for personalized patient stratification.
    BMC Cancer. 2019;19:1216.
    PubMed     Abstract available

  81. ZHOU J, Xia S, Li T, Liu R, et al
    Could aspirin be a lifesaver for prostate cancer patients in prostate cancer-specific mortality?: an update systematic review and meta-analysis.
    BMC Cancer. 2019;19:1186.
    PubMed     Abstract available

  82. RUI X, Shao S, Wang L, Leng J, et al
    Identification of recurrence marker associated with immune infiltration in prostate cancer with radical resection and build prognostic nomogram.
    BMC Cancer. 2019;19:1179.
    PubMed     Abstract available

    November 2019
  83. HUANG Z, Li G, Zhang Z, Gu R, et al
    beta2AR-HIF-1alpha-CXCL12 signaling of osteoblasts activated by isoproterenol promotes migration and invasion of prostate cancer cells.
    BMC Cancer. 2019;19:1142.
    PubMed     Abstract available

  84. GUO W, Sun YC, Bi JQ, He XY, et al
    Hypofractionated radiotherapy versus conventional radiotherapy in patients with intermediate- to high-risk localized prostate cancer: a meta-analysis of randomized controlled trials.
    BMC Cancer. 2019;19:1063.
    PubMed     Abstract available

    October 2019
  85. SEMAAN L, Mander N, Cher ML, Chinni SR, et al
    TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model.
    BMC Cancer. 2019;19:972.
    PubMed     Abstract available

  86. DONNELLY DW, Vis LC, Kearney T, Sharp L, et al
    Quality of life among symptomatic compared to PSA-detected prostate cancer survivors - results from a UK wide patient-reported outcomes study.
    BMC Cancer. 2019;19:947.
    PubMed     Abstract available

  87. WEIDEMANN SA, Sauer C, Luebke AM, Moller-Koop C, et al
    High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer.
    BMC Cancer. 2019;19:944.
    PubMed     Abstract available

    September 2019
  88. MARVASO G, Ciardo D, Corrao G, Gandini S, et al
    Radioablation +/- hormonotherapy for prostate cancer oligorecurrences (Radiosa trial): potential of imaging and biology (AIRC IG-22159).
    BMC Cancer. 2019;19:903.
    PubMed     Abstract available

  89. REN ZJ, Cao DH, Zhang Q, Ren PW, et al
    First-degree family history of breast cancer is associated with prostate cancer risk: a systematic review and meta-analysis.
    BMC Cancer. 2019;19:871.
    PubMed     Abstract available

    August 2019
  90. LAWRANCE S, Bui C, Mahindra V, Arcorace M, et al
    Assessing a modified-AJCC TNM staging system in the New South Wales Cancer Registry, Australia.
    BMC Cancer. 2019;19:850.
    PubMed     Abstract available

  91. PUENTE J, Gonzalez-Del-Alba A, Sala-Gonzalez N, Mendez-Vidal MJ, et al
    Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO).
    BMC Cancer. 2019;19:766.
    PubMed     Abstract available

    July 2019
  92. YANAI Y, Kosaka T, Hongo H, Oya M, et al
    Interstitial pneumonitis in a castration-resistant prostate cancer patient receiving cabazitaxel after thoracic radiation therapy: a case report.
    BMC Cancer. 2019;19:720.
    PubMed     Abstract available

  93. ZHU Y, Wang Y, Qian Z, Pan J, et al
    Extended lymphadenectomy for high-risk prostate cancer in patients with chronic lymphocytic leukemia may not be necessary: a report of two cases.
    BMC Cancer. 2019;19:676.
    PubMed     Abstract available

  94. ADLARD KN, Jenkins DG, Salisbury CE, Bolam KA, et al
    Peer support for the maintenance of physical activity and health in cancer survivors: the PEER trial - a study protocol of a randomised controlled trial.
    BMC Cancer. 2019;19:656.
    PubMed     Abstract available

    June 2019
  95. ENDEPOLS H, Morgenroth A, Zlatopolskiy BD, Krapf P, et al
    Peripheral ganglia in healthy rats as target structures for the evaluation of PSMA imaging agents.
    BMC Cancer. 2019;19:633.
    PubMed     Abstract available

  96. KIENER M, Chen L, Krebs M, Grosjean J, et al
    miR-221-5p regulates proliferation and migration in human prostate cancer cells and reduces tumor growth in vivo.
    BMC Cancer. 2019;19:627.
    PubMed     Abstract available

  97. BECKMANN K, Russell B, Josephs D, Garmo H, et al
    Chronic inflammatory diseases, anti-inflammatory medications and risk of prostate cancer: a population-based case-control study.
    BMC Cancer. 2019;19:612.
    PubMed     Abstract available

  98. KAPOOR R, Deek MP, McIntyre R, Raman N, et al
    A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA).
    BMC Cancer. 2019;19:572.
    PubMed     Abstract available

  99. KOSAKA T, Hongo H, Oya M
    Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report.
    BMC Cancer. 2019;19:562.
    PubMed     Abstract available

    May 2019
  100. SCHIFF JP, Cotogno P, Feibus A, Steinwald P, et al
    Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer.
    BMC Cancer. 2019;19:524.
    PubMed     Abstract available

  101. KANAN AD, Corey E, Vencio RZN, Ishwar A, et al
    Lineage relationship between prostate adenocarcinoma and small cell carcinoma.
    BMC Cancer. 2019;19:518.
    PubMed     Abstract available

  102. WERUTSKY G, Maluf FC, Cronemberger EH, Carrera Souza V, et al
    The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels.
    BMC Cancer. 2019;19:487.
    PubMed     Abstract available

  103. BURM R, Thewes B, Rodwell L, Kievit W, et al
    Long-term efficacy and cost-effectiveness of blended cognitive behavior therapy for high fear of recurrence in breast, prostate and colorectal Cancer survivors: follow-up of the SWORD randomized controlled trial.
    BMC Cancer. 2019;19:462.
    PubMed     Abstract available

  104. GEORGESCU C, Corbin JM, Thibivilliers S, Webb ZD, et al
    A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
    BMC Cancer. 2019;19:423.
    PubMed     Abstract available

    April 2019
  105. ZHANG Y, Li F, Liu L, Jiang H, et al
    Salinomycin triggers endoplasmic reticulum stress through ATP2A3 upregulation in PC-3 cells.
    BMC Cancer. 2019;19:381.
    PubMed     Abstract available

  106. FRANKLAND J, Brodie H, Cooke D, Foster C, et al
    Follow-up care after treatment for prostate cancer: evaluation of a supported self-management and remote surveillance programme.
    BMC Cancer. 2019;19:368.
    PubMed     Abstract available

  107. DULSKAS A, Cereska V, Zurauskas E, Stratilatovas E, et al
    Prostate cancer solitary metastasis to anal canal: case report and review of literature.
    BMC Cancer. 2019;19:374.
    PubMed     Abstract available

  108. TIWARI A, Mukherjee B, Hassan MK, Pattanaik N, et al
    Reduced FRG1 expression promotes prostate cancer progression and affects prostate cancer cell migration and invasion.
    BMC Cancer. 2019;19:346.
    PubMed     Abstract available

  109. IGUCHI T, Tamada S, Kato M, Yasuda S, et al
    Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study).
    BMC Cancer. 2019;19:339.
    PubMed     Abstract available

  110. NEIL-SZTRAMKO SE, Medysky ME, Campbell KL, Bland KA, et al
    Attention to the principles of exercise training in exercise studies on prostate cancer survivors: a systematic review.
    BMC Cancer. 2019;19:321.
    PubMed     Abstract available

  111. PARIKH NR, Huiza C, Patel JS, Tsai S, et al
    Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease.
    BMC Cancer. 2019;19:291.
    PubMed     Abstract available

    March 2019
  112. MAMIDI TKK, Wu J, Hicks C
    Integrating germline and somatic variation information using genomic data for the discovery of biomarkers in prostate cancer.
    BMC Cancer. 2019;19:229.
    PubMed     Abstract available

  113. SCHROEDER C, Grell J, Hube-Magg C, Kluth M, et al
    Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancer.
    BMC Cancer. 2019;19:193.
    PubMed     Abstract available

  114. HUMMEL S, Kohlmann W, Kollmeyer TM, Jenkins R, et al
    The contribution of the rs55705857 G allele to familial cancer risk as estimated in the Utah population database.
    BMC Cancer. 2019;19:190.
    PubMed     Abstract available

    February 2019
  115. TERADA N, Kamoto T, Tsukino H, Mukai S, et al
    The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients.
    BMC Cancer. 2019;19:156.
    PubMed     Abstract available

  116. CHUNG WS, Lin CL
    Sleep disorders associated with risk of prostate cancer: a population-based cohort study.
    BMC Cancer. 2019;19:146.
    PubMed     Abstract available

    January 2019
  117. CALAIS J, Czernin J, Fendler WP, Elashoff D, et al
    Correction to: Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT].
    BMC Cancer. 2019;19:97.
    PubMed     Abstract available

  118. LI T, Sun X, Chen L
    Free testosterone value before radical prostatectomy is related to oncologic outcomes and post-operative erectile function.
    BMC Cancer. 2019;19:87.
    PubMed     Abstract available

  119. BOEGEMANN M, Khaksar S, Bera G, Birtle A, et al
    Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study.
    BMC Cancer. 2019;19:60.
    PubMed     Abstract available

  120. QIU X, Wang W, Li B, Cheng B, et al
    Targeting Ezh2 could overcome docetaxel resistance in prostate cancer cells.
    BMC Cancer. 2019;19:27.
    PubMed     Abstract available

  121. CALAIS J, Czernin J, Fendler WP, Elashoff D, et al
    Randomized prospective phase III trial of (68)Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT].
    BMC Cancer. 2019;19:18.
    PubMed     Abstract available

  122. HEIDENREICH A, Gillessen S, Heinrich D, Keizman D, et al
    Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.
    BMC Cancer. 2019;19:12.
    PubMed     Abstract available

  123. ALIBHAI SMH, Santa Mina D, Ritvo P, Tomlinson G, et al
    A phase II randomized controlled trial of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy.
    BMC Cancer. 2019;19:2.
    PubMed     Abstract available

    December 2018
  124. TAKUWA H, Tsuji W, Shintaku M, Yotsumoto F, et al
    Hormone signaling via androgen receptor affects breast cancer and prostate cancer in a male patient: A case report.
    BMC Cancer. 2018;18:1282.
    PubMed     Abstract available

  125. CULTRARA CN, Kozuch SD, Ramasundaram P, Heller CJ, et al
    GRP78 modulates cell adhesion markers in prostate Cancer and multiple myeloma cell lines.
    BMC Cancer. 2018;18:1263.
    PubMed     Abstract available

  126. BOSSAN A, Ottman R, Andl T, Hasan MF, et al
    Expression of FGD4 positively correlates with the aggressive phenotype of prostate cancer.
    BMC Cancer. 2018;18:1257.
    PubMed     Abstract available

  127. MAI Z, Zhou Z, Yan W, Xiao Y, et al
    The transverse and vertical distribution of prostate cancer in biopsy and radical prostatectomy specimens.
    BMC Cancer. 2018;18:1205.
    PubMed     Abstract available

    November 2018
  128. MARTINEZ-GONZALEZ NA, Neuner-Jehle S, Plate A, Rosemann T, et al
    Correction to: The effects of shared decision-making compared to usual care for prostate cancer screening decisions: a systematic review and meta-analysis.
    BMC Cancer. 2018;18:1196.
    PubMed     Abstract available

  129. ALVAREZ CS, Villamor E, Meza R, Rozek LS, et al
    Differences in prostate tumor characteristics and survival among religious groups in Songkhla, Thailand.
    BMC Cancer. 2018;18:1175.
    PubMed     Abstract available

  130. GHOSHAL A, Garmo H, Hammar N, Jungner I, et al
    Can pre-diagnostic serum levels of sodium and potassium predict prostate cancer survival?
    BMC Cancer. 2018;18:1169.
    PubMed     Abstract available

  131. JOACHIM C, Veronique-Baudin J, Ulric-Gervaise S, Macni J, et al
    Pattern of care of prostate cancer patients across the Martinique: results of a population-based study in the Caribbean.
    BMC Cancer. 2018;18:1130.
    PubMed     Abstract available

  132. GOTARDELO DR, Courrol LC, Bellini MH, de Oliveira Silva FR, et al
    Porphyrins are increased in the faeces of patients with prostate cancer: a case-control study.
    BMC Cancer. 2018;18:1090.
    PubMed     Abstract available

  133. NI J, Cozzi P, Beretov J, Duan W, et al
    Epithelial cell adhesion molecule (EpCAM) is involved in prostate cancer chemotherapy/radiotherapy response in vivo.
    BMC Cancer. 2018;18:1092.
    PubMed     Abstract available

  134. VAN DE WIEL HJ, Stuiver MM, May AM, van Grinsven S, et al
    (Cost-)effectiveness of an internet-based physical activity support program (with and without physiotherapy counselling) on physical activity levels of breast and prostate cancer survivors: design of the PABLO trial.
    BMC Cancer. 2018;18:1073.
    PubMed     Abstract available

  135. ZEIGLER-JOHNSON C, Hudson A, Glanz K, Spangler E, et al
    Performance of prostate cancer recurrence nomograms by obesity status: a retrospective analysis of a radical prostatectomy cohort.
    BMC Cancer. 2018;18:1061.
    PubMed     Abstract available

  136. CHUNG DY, Koh DH, Goh HJ, Kim MS, et al
    Clinical significance and predictors of oncologic outcome after radical prostatectomy for invisible prostate cancer on multiparametric MRI.
    BMC Cancer. 2018;18:1057.
    PubMed     Abstract available

    October 2018
  137. ALIBHAI SMH, Ritvo P, Santa Mina D, Sabiston C, et al
    Protocol for a phase III RCT and economic analysis of two exercise delivery methods in men with PC on ADT.
    BMC Cancer. 2018;18:1031.
    PubMed     Abstract available

  138. MARTINEZ-GONZALEZ NA, Neuner-Jehle S, Plate A, Rosemann T, et al
    The effects of shared decision-making compared to usual care for prostate cancer screening decisions: a systematic review and meta-analysis.
    BMC Cancer. 2018;18:1015.
    PubMed     Abstract available

  139. IVANOVIC RF, Viana NI, Morais DR, Moura C, et al
    miR-618: possible control over TIMP-1 and its expression in localized prostate cancer.
    BMC Cancer. 2018;18:992.
    PubMed     Abstract available

  140. MUSSAWY H, Viezens L, Schroeder M, Hettenhausen S, et al
    The bone microenvironment promotes tumor growth and tissue perfusion compared with striated muscle in a preclinical model of prostate cancer in vivo.
    BMC Cancer. 2018;18:979.
    PubMed     Abstract available

  141. JIVIDEN K, Kedzierska KZ, Yang CS, Szlachta K, et al
    Genomic analysis of DNA repair genes and androgen signaling in prostate cancer.
    BMC Cancer. 2018;18:960.
    PubMed     Abstract available

    August 2018
  142. PACYNA JE, Kim S, Yost K, Sedlacek H, et al
    The comparative effectiveness of decision aids in diverse populations with early stage prostate cancer: a study protocol for a cluster-randomized controlled trial in the NCI Community Oncology Research Program (NCORP), Alliance A191402CD.
    BMC Cancer. 2018;18:788.
    PubMed     Abstract available

    July 2018
  143. ULLRICH A, Rath HM, Otto U, Kerschgens C, et al
    Return to work in prostate cancer survivors - findings from a prospective study on occupational reintegration following a cancer rehabilitation program.
    BMC Cancer. 2018;18:751.
    PubMed     Abstract available

  144. ORTELLI L, Spitale A, Mazzucchelli L, Bordoni A, et al
    Quality indicators of clinical cancer care for prostate cancer: a population-based study in southern Switzerland.
    BMC Cancer. 2018;18:733.
    PubMed     Abstract available

    June 2018
  145. GREGOIRE C, Nicolas H, Bragard I, Delevallez F, et al
    Efficacy of a hypnosis-based intervention to improve well-being during cancer: a comparison between prostate and breast cancer patients.
    BMC Cancer. 2018;18:677.
    PubMed     Abstract available

  146. GREASLEY RU, Turner R, Collins K, Brown J, et al
    Treatment in the STAMPEDE era for castrate resistant prostate cancer in the UK: ongoing challenges and underappreciated clinical problems.
    BMC Cancer. 2018;18:667.
    PubMed     Abstract available

    May 2018
  147. KASHIWABARA T, Suda S
    Usefulness of combined androgen blockade therapy with gonadotropin-releasing hormone antagonist for bone metastatic prostate cancer with pretreatment prostate-specific antigen level >/= 50 ng/mL.
    BMC Cancer. 2018;18:619.
    PubMed     Abstract available

  148. HEINRICH MC, Gobel C, Kluth M, Bernreuther C, et al
    PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer.
    BMC Cancer. 2018;18:612.
    PubMed     Abstract available

  149. MOSAAD E, Chambers K, Futrega K, Clements J, et al
    Using high throughput microtissue culture to study the difference in prostate cancer cell behavior and drug response in 2D and 3D co-cultures.
    BMC Cancer. 2018;18:592.
    PubMed     Abstract available

  150. RICHARDSON M, Sidhom M, Gallagher S, Grand M, et al
    PROstate Multicentre External beam radioTHErapy Using a Stereotactic boost: the PROMETHEUS study protocol.
    BMC Cancer. 2018;18:588.
    PubMed     Abstract available

  151. PASQUIER D, Bogart E, Bonodeau F, Lacornerie T, et al
    BioPro-RCMI-1505 trial: multicenter study evaluating the use of a biodegradable balloon for the treatment of intermediate risk prostate cancer by intensity modulated radiotherapy; study protocol.
    BMC Cancer. 2018;18:566.
    PubMed     Abstract available

  152. PARK JW, Koh DH, Jang WS, Cho KS, et al
    Predictors of adverse pathologic features after radical prostatectomy in low-risk prostate cancer.
    BMC Cancer. 2018;18:545.
    PubMed     Abstract available

  153. UEMURA K, Miyoshi Y, Kawahara T, Ryosuke J, et al
    Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxel.
    BMC Cancer. 2018;18:501.
    PubMed     Abstract available

    April 2018
  154. RYE MB, Bertilsson H, Andersen MK, Rise K, et al
    Cholesterol synthesis pathway genes in prostate cancer are transcriptionally downregulated when tissue confounding is minimized.
    BMC Cancer. 2018;18:478.
    PubMed     Abstract available

  155. KOO KC, Lee JS, Kim JW, Han KS, et al
    Impact of clinical trial participation on survival in patients with castration-resistant prostate cancer: a multi-center analysis.
    BMC Cancer. 2018;18:468.
    PubMed     Abstract available

  156. JONES DZ, Schmidt ML, Suman S, Hobbing KR, et al
    Micro-RNA-186-5p inhibition attenuates proliferation, anchorage independent growth and invasion in metastatic prostate cancer cells.
    BMC Cancer. 2018;18:421.
    PubMed     Abstract available

  157. DAWSON JK, Dorff TB, Todd Schroeder E, Lane CJ, et al
    Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial.
    BMC Cancer. 2018;18:368.
    PubMed     Abstract available

  158. TOSCO L, Laenen A, Gevaert T, Salmon I, et al
    Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial.
    BMC Cancer. 2018;18:354.
    PubMed     Abstract available

  159. BOWLER E, Porazinski S, Uzor S, Thibault P, et al
    Hypoxia leads to significant changes in alternative splicing and elevated expression of CLK splice factor kinases in PC3 prostate cancer cells.
    BMC Cancer. 2018;18:355.
    PubMed     Abstract available

    March 2018
  160. LIANG W, Song L, Peng Z, Zou Y, et al
    Possible association between androgenic alopecia and risk of prostate cancer and testicular germ cell tumor: a systematic review and meta-analysis.
    BMC Cancer. 2018;18:279.
    PubMed     Abstract available

  161. KIM M, Song C, Jeong IG, Choi SK, et al
    Androgen deprivation therapy during and after post-prostatectomy radiotherapy in patients with prostate cancer: a case control study.
    BMC Cancer. 2018;18:271.
    PubMed     Abstract available

  162. CARAM MEV, Estes JP, Griggs JJ, Lin P, et al
    Temporal and geographic variation in the systemic treatment of advanced prostate cancer.
    BMC Cancer. 2018;18:258.
    PubMed     Abstract available

    February 2018
  163. BOSCO C, Garmo H, Hammar N, Walldius G, et al
    Glucose, lipids and gamma-glutamyl transferase measured before prostate cancer diagnosis and secondly diagnosed primary tumours: a prospective study in the Swedish AMORIS cohort.
    BMC Cancer. 2018;18:205.
    PubMed     Abstract available

  164. IBRAHIM M, Yadav S, Ogunleye F, Zakalik D, et al
    Male BRCA mutation carriers: clinical characteristics and cancer spectrum.
    BMC Cancer. 2018;18:179.
    PubMed     Abstract available

  165. JIMENEZ-MENDOZA E, Vazquez-Salas RA, Barrientos-Gutierrez T, Reynales-Shigematsu LM, et al
    Smoking and prostate cancer: a life course analysis.
    BMC Cancer. 2018;18:160.
    PubMed     Abstract available

  166. FORT RS, Matho C, Geraldo MV, Ottati MC, et al
    Nc886 is epigenetically repressed in prostate cancer and acts as a tumor suppressor through the inhibition of cell growth.
    BMC Cancer. 2018;18:127.
    PubMed     Abstract available

    January 2018
  167. LANGE M, Laviec H, Castel H, Heutte N, et al
    Correction to: Impact of new generation hormone-therapy on cognitive function in elderly patients treated for a metastatic prostate cancer: Cog-Pro trial protocol.
    BMC Cancer. 2018;18:110.
    PubMed     Abstract available

  168. MACIEL-SILVA P, Caldeira I, de Assis Santos I, Carreira ACO, et al
    FAM3B/PANDER inhibits cell death and increases prostate tumor growth by modulating the expression of Bcl-2 and Bcl-XL cell survival genes.
    BMC Cancer. 2018;18:90.
    PubMed     Abstract available

  169. SANGHERA S, Coast J, Martin RM, Donovan JL, et al
    Cost-effectiveness of prostate cancer screening: a systematic review of decision-analytical models.
    BMC Cancer. 2018;18:84.
    PubMed     Abstract available

  170. GUERTIN MH, Robitaille K, Pelletier JF, Duchesne T, et al
    Effects of concentrated long-chain omega-3 polyunsaturated fatty acid supplementation before radical prostatectomy on prostate cancer proliferation, inflammation, and quality of life: study protocol for a phase IIb, randomized, double-blind, placebo-c
    BMC Cancer. 2018;18:64.
    PubMed     Abstract available

  171. CHEN CB, Eskin M, Eurich DT, Majumdar SR, et al
    Metformin, Asian ethnicity and risk of prostate cancer in type 2 diabetes: a systematic review and meta-analysis.
    BMC Cancer. 2018;18:65.
    PubMed     Abstract available

  172. HEUMANN A, Heinemann N, Hube-Magg C, Lang DS, et al
    High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer.
    BMC Cancer. 2018;18:37.
    PubMed     Abstract available

  173. DEPCZYNSKI J, Dobbins T, Armstrong B, Lower T, et al
    Comparison of cancer incidence in Australian farm residents 45 years and over, compared to rural non-farm and urban residents - a data linkage study.
    BMC Cancer. 2018;18:33.
    PubMed     Abstract available

  174. PARK SY, Park JW, Lee GW, Li L, et al
    Inhibition of neddylation facilitates cell migration through enhanced phosphorylation of caveolin-1 in PC3 and U373MG cells.
    BMC Cancer. 2018;18:30.
    PubMed     Abstract available

  175. BOTTCHER R, Kweldam CF, Livingstone J, Lalonde E, et al
    Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations.
    BMC Cancer. 2018;18:8.
    PubMed     Abstract available

  176. PESTOVA K, Koch AJ, Quesenberry CP, Shan J, et al
    Identification of fluorescence in situ hybridization assay markers for prediction of disease progression in prostate cancer patients on active surveillance.
    BMC Cancer. 2018;18:2.
    PubMed     Abstract available

    December 2017
  177. YANG KQ, Liu Y, Huang QH, Mo N, et al
    Bone marrow-derived mesenchymal stem cells induced by inflammatory cytokines produce angiogenetic factors and promote prostate cancer growth.
    BMC Cancer. 2017;17:878.
    PubMed     Abstract available

  178. DAMODARAN S, Damaschke N, Gawdzik J, Yang B, et al
    Dysregulation of Sirtuin 2 (SIRT2) and histone H3K18 acetylation pathways associates with adverse prostate cancer outcomes.
    BMC Cancer. 2017;17:874.
    PubMed     Abstract available

  179. BEEBE-DIMMER JL, Yee C, Paskett E, Schwartz AG, et al
    Family history of prostate and colorectal cancer and risk of colorectal cancer in the Women's health initiative.
    BMC Cancer. 2017;17:848.
    PubMed     Abstract available

  180. EGGLY S, Hamel LM, Heath E, Manning MA, et al
    Partnering around cancer clinical trials (PACCT): study protocol for a randomized trial of a patient and physician communication intervention to increase minority accrual to prostate cancer clinical trials.
    BMC Cancer. 2017;17:807.
    PubMed     Abstract available

    November 2017
  181. KANG YJ, Jang WS, Kwon JK, Yoon CY, et al
    Intermediate PSA half-life after neoadjuvant hormone therapy predicts reduced risk of castration-resistant prostate cancer development after radical prostatectomy.
    BMC Cancer. 2017;17:789.
    PubMed     Abstract available

  182. SAIFUDDIN SR, Devlies W, Santaolalla A, Cahill F, et al
    King's Health Partners' Prostate Cancer Biobank (KHP PCaBB).
    BMC Cancer. 2017;17:784.
    PubMed     Abstract available

  183. TSAI HK, Lehrer J, Alshalalfa M, Erho N, et al
    Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma.
    BMC Cancer. 2017;17:759.
    PubMed     Abstract available

  184. CINDOLO L, Natoli C, De Nunzio C, De Tursi M, et al
    Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter "real life" study.
    BMC Cancer. 2017;17:753.
    PubMed     Abstract available

  185. ENDZELINS E, Berger A, Melne V, Bajo-Santos C, et al
    Detection of circulating miRNAs: comparative analysis of extracellular vesicle-incorporated miRNAs and cell-free miRNAs in whole plasma of prostate cancer patients.
    BMC Cancer. 2017;17:730.
    PubMed     Abstract available

  186. ERNST J, Mehnert A, Dietz A, Hornemann B, et al
    Perceived stigmatization and its impact on quality of life - results from a large register-based study including breast, colon, prostate and lung cancer patients.
    BMC Cancer. 2017;17:741.
    PubMed     Abstract available

  187. JIANN BP
    Does hair dye use really increase the risk of prostate cancer?
    BMC Cancer. 2017;17:724.
    PubMed     Abstract available

    October 2017
  188. KIRKMAN M, Young K, Evans S, Millar J, et al
    Men's perceptions of prostate cancer diagnosis and care: insights from qualitative interviews in Victoria, Australia.
    BMC Cancer. 2017;17:704.
    PubMed     Abstract available

  189. IZUMI K, Mizokami A, Namiki M, Inoue S, et al
    Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial.
    BMC Cancer. 2017;17:677.
    PubMed     Abstract available

  190. WITTMANN D, Mehta A, Northouse L, Dunn R, et al
    TrueNTH sexual recovery study protocol: a multi-institutional collaborative approach to developing and testing a web-based intervention for couples coping with the side-effects of prostate cancer treatment in a randomized controlled trial.
    BMC Cancer. 2017;17:664.
    PubMed     Abstract available

    September 2017
  191. ABHYANKAR N, Hoskins KF, Abern MR, Calip GS, et al
    Descriptive characteristics of prostate cancer in patients with a history of primary male breast cancer - a SEER analysis.
    BMC Cancer. 2017;17:659.
    PubMed     Abstract available

  192. FRANKLAND J, Brodie H, Cooke D, Foster C, et al
    Follow-up care after treatment for prostate cancer: protocol for an evaluation of a nurse-led supported self-management and remote surveillance programme.
    BMC Cancer. 2017;17:656.
    PubMed     Abstract available

  193. PASCALE M, Azinwi CN, Marongiu B, Pesce G, et al
    The outcome of prostate cancer patients treated with curative intent strongly depends on survival after metastatic progression.
    BMC Cancer. 2017;17:651.
    PubMed     Abstract available

  194. SONG W, Soni V, Soni S, Khera M, et al
    Testosterone inhibits the growth of prostate cancer xenografts in nude mice.
    BMC Cancer. 2017;17:635.
    PubMed     Abstract available

  195. GONNISSEN A, Isebaert S, Perneel C, McKee CM, et al
    Tissue microarray analysis indicates hedgehog signaling as a potential prognostic factor in intermediate-risk prostate cancer.
    BMC Cancer. 2017;17:634.
    PubMed     Abstract available

  196. MITRA R, Le TT, Gorjala P, Goodman OB Jr, et al
    Positive regulation of prostate cancer cell growth by lipid droplet forming and processing enzymes DGAT1 and ABHD5.
    BMC Cancer. 2017;17:631.
    PubMed     Abstract available

  197. WANG H, Gu L, Wu Y, Feng D, et al
    The values of neutrophil-lymphocyte ratio and/or prostate-specific antigen in discriminating real Gleason score >/= 7 prostate cancer from group of biopsy-based Gleason score </= 6.
    BMC Cancer. 2017;17:629.
    PubMed     Abstract available

  198. TANAKA N, Nakai Y, Miyake M, Anai S, et al
    Trends in risk classification and primary therapy of Japanese patients with prostate cancer in Nara urological research and treatment group (NURTG) - comparison between 2004-2006, 2007-2009, and 2010-2012.
    BMC Cancer. 2017;17:616.
    PubMed     Abstract available

    August 2017
  199. KINNUNEN PTT, Murtola TJ, Talala K, Taari K, et al
    Prostate cancer-specific survival among warfarin users in the Finnish Randomized Study of Screening for Prostate Cancer.
    BMC Cancer. 2017;17:585.
    PubMed     Abstract available

  200. TANAKA N, Asakawa I, Nakai Y, Miyake M, et al
    Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated radiation therapy for prostate cancer.
    BMC Cancer. 2017;17:573.
    PubMed     Abstract available

  201. QIU J, Peng S, Si-Tu J, Hu C, et al
    Erratum to: Identification of endonuclease domain-containing 1 as a novel tumor suppressor in prostate cancer.
    BMC Cancer. 2017;17:569.

  202. LANGE M, Laviec H, Castel H, Heutte N, et al
    Impact of new generation hormone-therapy on cognitive function in elderly patients treated for a metastatic prostate cancer: Cog-Pro trial protocol.
    BMC Cancer. 2017;17:549.
    PubMed     Abstract available

  203. BECKMANN KR, Vincent AD, O'Callaghan ME, Cohen P, et al
    Oncological outcomes in an Australian cohort according to the new prostate cancer grading groupings.
    BMC Cancer. 2017;17:537.
    PubMed     Abstract available

  204. LAO C, Edlin R, Rouse P, Brown C, et al
    The cost-effectiveness of active surveillance compared to watchful waiting and radical prostatectomy for low risk localised prostate cancer.
    BMC Cancer. 2017;17:529.
    PubMed     Abstract available

    July 2017
  205. JACOBSEN F, Taskin B, Melling N, Sauer C, et al
    Increased ERCC1 expression is linked to chromosomal aberrations and adverse tumor biology in prostate cancer.
    BMC Cancer. 2017;17:504.
    PubMed     Abstract available

  206. CRAWLEY D, Chandra A, Loda M, Gillett C, et al
    Metformin and longevity (METAL): a window of opportunity study investigating the biological effects of metformin in localised prostate cancer.
    BMC Cancer. 2017;17:494.
    PubMed     Abstract available

  207. LANGIUS-EKLOF A, Crafoord MT, Christiansen M, Fjell M, et al
    Effects of an interactive mHealth innovation for early detection of patient-reported symptom distress with focus on participatory care: protocol for a study based on prospective, randomised, controlled trials in patients with prostate and breast cance
    BMC Cancer. 2017;17:466.
    PubMed     Abstract available

  208. GRANT DJ, Chen Z, Howard LE, Wiggins E, et al
    UDP-glucuronosyltransferases and biochemical recurrence in prostate cancer progression.
    BMC Cancer. 2017;17:463.
    PubMed     Abstract available

    June 2017
  209. RADWAN N, Phillips R, Ross A, Rowe SP, et al
    A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).
    BMC Cancer. 2017;17:453.
    PubMed     Abstract available

  210. GOLSTEIJN RHJ, Bolman C, Volders E, Peels DA, et al
    Development of a computer-tailored physical activity intervention for prostate and colorectal cancer patients and survivors: OncoActive.
    BMC Cancer. 2017;17:446.
    PubMed     Abstract available

    May 2017
  211. TAN G, Qiu M, Chen L, Zhang S, et al
    JS-K, a nitric oxide pro-drug, regulates growth and apoptosis through the ubiquitin-proteasome pathway in prostate cancer cells.
    BMC Cancer. 2017;17:376.
    PubMed     Abstract available

  212. MANCARELLA C, Casanova-Salas I, Calatrava A, Garcia-Flores M, et al
    Insulin-like growth factor 1 receptor affects the survival of primary prostate cancer patients depending on TMPRSS2-ERG status.
    BMC Cancer. 2017;17:367.
    PubMed     Abstract available

  213. QIU J, Peng S, Si-Tu J, Hu C, et al
    Identification of endonuclease domain-containing 1 as a novel tumor suppressor in prostate cancer.
    BMC Cancer. 2017;17:360.
    PubMed     Abstract available

  214. HABL G, Straube C, Schiller K, Duma MN, et al
    Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT).
    BMC Cancer. 2017;17:361.
    PubMed     Abstract available

  215. KAWAKAMI K, Fujita Y, Matsuda Y, Arai T, et al
    Gamma-glutamyltransferase activity in exosomes as a potential marker for prostate cancer.
    BMC Cancer. 2017;17:316.
    PubMed     Abstract available

    April 2017
  216. KIRBY MK, Ramaker RC, Roberts BS, Lasseigne BN, et al
    Genome-wide DNA methylation measurements in prostate tissues uncovers novel prostate cancer diagnostic biomarkers and transcription factor binding patterns.
    BMC Cancer. 2017;17:273.
    PubMed     Abstract available

  217. NGOLLO M, Lebert A, Daures M, Judes G, et al
    Global analysis of H3K27me3 as an epigenetic marker in prostate cancer progression.
    BMC Cancer. 2017;17:261.
    PubMed     Abstract available

    March 2017
  218. BERNTSEN S, Aaronson NK, Buffart L, Borjeson S, et al
    Design of a randomized controlled trial of physical training and cancer (Phys-Can) - the impact of exercise intensity on cancer related fatigue, quality of life and disease outcome.
    BMC Cancer. 2017;17:218.
    PubMed     Abstract available

  219. KEALL P, Nguyen DT, O'Brien R, Booth J, et al
    Stereotactic prostate adaptive radiotherapy utilising kilovoltage intrafraction monitoring: the TROG 15.01 SPARK trial.
    BMC Cancer. 2017;17:180.
    PubMed     Abstract available

    February 2017
  220. MEDENWALD D, Vordermark D, Dietzel CT
    Cancer mortality in former East and West Germany: a story of unification?
    BMC Cancer. 2017;17:94.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.